Compass Therapeutics, Inc. (CMPX) News
Follow Compass Therapeutics, Inc. (CMPX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: FDA request trims CMPX ~30% and COMPANION-002 shows ORR/PFS
Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) plunged ~30%, wiping out about $104M after the FDA sought more survival data for tovecimig's BLA, even as Phase 2/3 COMPANION-002 showed higher ORR and longer PFS for to
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Compass Therapeutics Price Target Cut to $8.00/Share From $15.00 by Craig-Hallum
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 05:45 PM UTC
L
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
Shares of Compass Therapeutics (CMPX) fell more than 6% on Wednesday, heading for a third straight decline as analysts cut their price targets after a regulatory setback for the biotech’s lead cancer drug, Tovecimig.CMPX
REGULATION | Sep 23, 2026, 01:45 PM UTC
L
Compass Therapeutics Is Maintained at Market Outperform by Citizens
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:57 PM UTC
L
Compass Therapeutics Is Maintained at Buy by Guggenheim
Ratings actions from Benzinga: GMT) Compass Therapeutics Price Target Cut to $4.00/Share From $8.00 by GuggenheimRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:47 PM UTC
L
Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target
Citizens maintained their Market Outperform rating on Compass Therapeutics's stock with a price target of $4.00.The price target implies an upside of 222.6% from the Sep 22 close of $1.24.Key takeaways from the analyst n
EQUITY | Sep 23, 2026, 12:47 PM UTC
L
Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target
Guggenheim maintained their Buy rating on Compass Therapeutics's stock with a price target of $4.00.The price target implies an upside of 222.6% from the Sep 22 close of $1.24.Key takeaways from the analyst noteStrong Pi
EQUITY | Sep 23, 2026, 12:37 PM UTC
L
Compass Therapeutics Cut to Neutral From Outperform by Wedbush
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:22 PM UTC
L
Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1
Wedbush downgraded Compass Therapeutics's stock to Neutral with a price target of $1.00.The price target implies a downside of 19.4% from the Sep 22 close of $1.24.Key takeaways from the analyst noteRegulatory Challenges
REGULATION | Sep 23, 2026, 12:12 PM UTC
L
Compass Therapeutics Price Target Cut to $12.00/Share From $24.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:48 AM UTC
L
HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target
HC Wainwright & Co. maintained their Buy rating on Compass Therapeutics's stock with a price target of $12.00.The price target implies an upside of 867.7% from the Sep 22 close of $1.24.Key takeaways from the analyst not
EQUITY | Sep 23, 2026, 10:38 AM UTC
L
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
Shares of Compass Therapeutics (CMPX) plunged about 32% on Tuesday, clocking their worst day since April, after the U.S. Food and Drug Administration (FDA) said the company should run a new survival study before filing f
REGULATION | Sep 22, 2026, 11:07 PM UTC
M
CMPX shares slump after FDA recommends additional cancer trial
Compass Therapeutics shares fell more than 25% after the FDA recommended an additional trial for its lead cancer drug, potentially delaying commercialization.
REGULATION | Sep 22, 2026, 02:43 PM UTC
L
CMPX - Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
CMPX - Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
REGULATION | Sep 22, 2026, 12:34 PM UTC
L
CMPX - Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
CMPX - Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
EARNINGS | Aug 06, 2026, 11:30 AM UTC
H
CMPX Compass Therapeutics announces tovecimig data accepted for an oral presentation at the esmo Congress 2026
CMPX Compass Therapeutics announces tovecimig data accepted for an oral presentation at the esmo Congress 2026
GEOPOLITICS | Jul 17, 2026, 02:42 PM UTC